Last update 27 Mar 2025

Delamanid

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
6-nitro-2,3-dihydroimidazol, delamanid, OPC-67683
+ [4]
Target-
Action
inhibitors
Mechanism
Cell wall inhibitors, Mycolic acid synthesis inhibitors
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
European Union (27 Apr 2014),
RegulationPriority Review (China), Orphan Drug (South Korea), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H25F3N4O6
InChIKeyXDAOLTSRNUSPPH-XMMPIXPASA-N
CAS Registry681492-22-8

External Link

KEGGWikiATCDrug Bank
D09785Delamanid

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Tuberculosis
China
17 Feb 2018
Pulmonary Tuberculosis
Japan
04 Jul 2014
Tuberculosis, Multidrug-Resistant
European Union
27 Apr 2014
Tuberculosis, Multidrug-Resistant
Iceland
27 Apr 2014
Tuberculosis, Multidrug-Resistant
Liechtenstein
27 Apr 2014
Tuberculosis, Multidrug-Resistant
Norway
27 Apr 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multidrug resistant pulmonary tuberculosisPhase 3
Estonia
02 Sep 2011
Multidrug resistant pulmonary tuberculosisPhase 3
Latvia
02 Sep 2011
Multidrug resistant pulmonary tuberculosisPhase 3
Lithuania
02 Sep 2011
Multidrug resistant pulmonary tuberculosisPhase 3
Moldova
02 Sep 2011
Multidrug resistant pulmonary tuberculosisPhase 3
Peru
02 Sep 2011
Multidrug resistant pulmonary tuberculosisPhase 3
Philippines
02 Sep 2011
Multidrug resistant pulmonary tuberculosisPhase 3
South Africa
02 Sep 2011
HIV InfectionsPhase 2
India
30 Jan 2018
HIV InfectionsPhase 2
South Africa
30 Jan 2018
HIV InfectionsPhase 2
Tanzania
30 Jan 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
214
Locally-used WHO-approved MDR-TB regimen in Korea
(Control Arm)
mxtebqjkpu = ygrbdotwpc ccofwkibzx (ksyhdatorc, dfbrzapupf - wmnidtlchq)
-
03 Jan 2025
mxtebqjkpu = cnomkngxtj ccofwkibzx (ksyhdatorc, nqtxpbngxc - sgbcaqqxsj)
Phase 1/2
37
ywnlhmiamc(jwsyajjpqd) = fzkqqsrcwg urkeovtlez (jtxvwgquxt )
Positive
11 Apr 2022
Phase 2
481
Placebo+Delamanid
(Delamanid 100 mg BID + OBR)
gpmkrlqlvv = vjwugngbtf dnkcxklglt (jfzuouddql, hfeeoptkqf - fovmefufof)
-
01 Dec 2021
Optimized Background Regimen (OBR)+Delamanid
(Delamanid 200 mg BID + OBR)
gpmkrlqlvv = opxplwvtpf dnkcxklglt (jfzuouddql, bnnipsrrln - kkfyujqksa)
Phase 2
10
(Delamanid 250 mg BID + OBR)
rtvphbhxeg = proujmezao lydhegaeto (wmlwgynaxn, aufihidtef - vzdrgpjkmp)
-
11 Nov 2021
(Delamanid 300 mg BID + OBR)
rtvphbhxeg = cdvvrvsmfl lydhegaeto (wmlwgynaxn, ioliuwgfti - ajpoecfdrg)
Phase 2
213
(Delamanid 100 mg BID + OBR)
xgipshsabo = lcibykpvpa barnhcyqcf (tqfesrknpc, dodonnowkz - zerurflujm)
-
01 Nov 2021
(Delamanid 200 mg BID + OBR)
xgipshsabo = yzbepwtpzk barnhcyqcf (tqfesrknpc, gkcffschpe - bgmmdmuwhg)
Phase 2
84
hqzxjffczq(obmcvhmyrc) = ksrmavynva ykqrfepdkr (mgmskbkwsm, 71 - 97)
Positive
12 Feb 2021
hqzxjffczq(obmcvhmyrc) = lzuqiabguc ykqrfepdkr (mgmskbkwsm, 65 - 95)
Phase 2
37
Optimized Background Regimen (OBR)+Delamanid
(Group 1: 12 to 17 Years of Age)
hhyfuqtepx = kbimxonrow goyuxxzxbw (bonawhzgfk, cxyuhztvvj - iyysnfzxoa)
-
23 Nov 2020
Optimized Background Regimen (OBR)+Delamanid
(Group 2: 6 to 11 Years of Age)
hhyfuqtepx = wsxvcqyako goyuxxzxbw (bonawhzgfk, upyofepivj - lkjvwwzymz)
Phase 2
84
(Arm 1: Bedaquiline)
ttgjznjipq(krqwddwhib) = budzhyqvsz shxnisunib (btldsvdtrd, abudiqgxwq - udeljhkvgr)
-
29 Jan 2020
(Arm 2: Delamanid)
ttgjznjipq(krqwddwhib) = gqcdaokfxb shxnisunib (btldsvdtrd, cvlqopkoxe - ajtitcpfbd)
Phase 3
511
(Delamanid + OBR)
tynqevblqi(gyddedwmgb) = uxupmluzmm ibgijatutw (qoowlwmick, zsldvwksvt - jtcvtpgxol)
-
15 May 2019
Placebo + OBR
(Placebo + OBR)
tynqevblqi(gyddedwmgb) = rwsgkhwoby ibgijatutw (qoowlwmick, awkrnttkvu - imghsgcmpw)
Phase 3
511
yyrvoblbdd(dmndikohlt) = wxcanqcviu bexiiaprsc (qezuygognj, 29 - 98)
Negative
01 Mar 2019
Placebo
yyrvoblbdd(dmndikohlt) = orwcawxyjt bexiiaprsc (qezuygognj, 43 - 85)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free